8月21日，鱼跃医疗今日收盘36.69元，上涨1.35%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到20.77倍，创52天以来新低，总市值367.81亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均60.02倍，行业中值41.17倍，鱼跃医疗排 名第42位。 截至2025年一季报，共有69家机构持仓鱼跃医疗，其中基金69家，合计持股数5595.24万股，持股市值 19.92亿元。 江苏鱼跃医疗设备股份有限公司的主营业务是研发、制造和销售医疗器械产品及提供相关解决方案。公 司产品主要集中在呼吸制氧、糖尿病护理、感染控制解决方案、家用类电子检测及体外诊断、急救与临 床及康复器械等业务领域。公司目前拥有"鱼跃yuwell"、"洁芙柔"、"华佗Hwato"、"金钟JZ"、"安尔 碘"、"普美康PRIMEDIC"、"六六视觉"等几大主要品牌。"鱼跃"品牌深入人心，依托鱼跃产品力的不断 提升及有效的品牌传播，以及旗下产品在海内外医疗一线的卓越表现，公司品牌价值和品牌优势显著提 升。 最新一期业绩显示，2025年一季报，公司实现营业收入24.36亿元，同比9.17%；净利润6.25亿元，同 ...

7月31日，鱼跃医疗今日收盘34.88元，下跌1.77%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到19.74倍，总市值349.66亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.89倍，行业中值37.06倍，鱼跃医疗排 名第41位。 江苏鱼跃医疗设备股份有限公司的主营业务是研发、制造和销售医疗器械产品及提供相关解决方案。公 司产品主要集中在呼吸制氧、糖尿病护理、感染控制解决方案、家用类电子检测及体外诊断、急救与临 床及康复器械等业务领域。公司目前拥有"鱼跃yuwell"、"洁芙柔"、"华佗Hwato"、"金钟JZ"、"安尔 碘"、"普美康PRIMEDIC"、"六六视觉"等几大主要品牌。"鱼跃"品牌深入人心，依托鱼跃产品力的不断 提升及有效的品牌传播，以及旗下产品在海内外医疗一线的卓越表现，公司品牌价值和品牌优势显著提 升。 最新一期业绩显示，2025年一季报，公司实现营业收入24.36亿元，同比9.17%；净利润6.25亿元，同 比-5.26%，销售毛利率50.30%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)11鱼跃医疗19.7419.362.67349 ...

Core Viewpoint - Yuyue Medical's stock closed at 35.38 yuan, down 1.39%, with a rolling PE ratio of 20.03 times, and a total market value of 35.468 billion yuan [1][2] Company Overview - Jiangsu Yuyue Medical Equipment Co., Ltd. specializes in the research, manufacturing, and sales of medical device products, providing related solutions. The company's products focus on respiratory oxygen, diabetes care, infection control solutions, home electronic testing, in vitro diagnostics, emergency and clinical rehabilitation equipment [1] - The company owns several major brands, including "Yuyue," "Jiefurou," "Huatuo Hwato," "Jinzhong JZ," "An'er iodine," "Primedic," and "Liuliu Vision," with the "Yuyue" brand being well-recognized [1] Financial Performance - For the first quarter of 2025, the company reported operating revenue of 2.436 billion yuan, a year-on-year increase of 9.17%, and a net profit of 625 million yuan, a year-on-year decrease of 5.26%. The sales gross margin was 50.30% [2] - As of the first quarter of 2025, 69 institutions held shares in Yuyue Medical, with a total holding of 55.9524 million shares valued at 1.992 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 55.28 times, with a median of 38.06 times, placing Yuyue Medical at 41st in the industry ranking [1][2] - The company's PE (TTM) is 20.03, while the industry average is significantly higher at 55.28 [2]

7月7日，鱼跃医疗今日收盘34.71元，下跌2.66%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到19.65倍，总市值347.96亿元。 资金流向方面，7月7日，鱼跃医疗主力资金净流出3461.12万元，近5日总体呈流出状态，5日共流出 13176.85万元。 江苏鱼跃医疗设备股份有限公司的主营业务是研发、制造和销售医疗器械产品及提供相关解决方案。公 司产品主要集中在呼吸制氧、糖尿病护理、感染控制解决方案、家用类电子检测及体外诊断、急救与临 床及康复器械等业务领域。公司目前拥有"鱼跃yuwell"、"洁芙柔"、"华佗Hwato"、"金钟JZ"、"安尔 碘"、"普美康PRIMEDIC"、"六六视觉"等几大主要品牌。"鱼跃"品牌深入人心，依托鱼跃产品力的不断 提升及有效的品牌传播，以及旗下产品在海内外医疗一线的卓越表现，公司品牌价值和品牌优势显著提 升。 最新一期业绩显示，2025年一季报，公司实现营业收入24.36亿元，同比9.17%；净利润6.25亿元，同 比-5.26%，销售毛利率50.30%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13鱼跃医疗19.6519.272.65 ...

Core Insights - Yuyue Medical's stock closed at 35.8 yuan, with a PE ratio of 20.26, marking a new low in 26 days, and a total market capitalization of 35.889 billion yuan [1] - The average PE ratio in the medical device industry is 49.84, with a median of 36.65, placing Yuyue Medical at the 47th position [1][2] - As of April 18, 2025, Yuyue Medical has 40,000 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Yuyue Medical specializes in the research, manufacturing, and sales of medical devices, focusing on areas such as respiratory oxygen, diabetes care, infection control solutions, home electronic testing, in vitro diagnostics, emergency and clinical rehabilitation equipment [1] - The company owns several major brands, including "Yuyue," "Jiefuro," "Hua Tuo," "Jin Zhong," "An Er Iodine," "Primedic," and "Liuliu Vision," with significant brand value and advantages due to product performance and effective brand communication [1] Financial Performance - In Q1 2025, Yuyue Medical reported revenue of 2.436 billion yuan, a year-on-year increase of 9.17%, while net profit was 625 million yuan, reflecting a year-on-year decrease of 5.26%, with a gross profit margin of 50.30% [2] - The company's PE (TTM) is 20.26, with a static PE of 19.88 and a price-to-book ratio of 2.74 [2]